Key terms
About AXGN
Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm’s products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest AXGN news
Today
7:13am ET
AxoGen Updates Corporate Presentation for Stakeholders
Apr 29
4:51pm ET
AxoGen announces first surgical implants of Avive+ soft tissue matrix
Mar 07
1:01am ET
New Accounting & Financial Operations Risk for AxoGen – What’s the Latest?
Mar 06
11:17pm ET
Axogen’s Strong Growth Prospects and Positive Analyst Outlook Prompt Buy Rating and Increased Price Target
Mar 06
8:54am ET
AxoGen files $100M mixed securities shelf
Mar 06
12:35am ET
Buy Rating Affirmed: AxoGen’s Robust Growth and Market Potential Drive Positive Outlook
Mar 05
4:43pm ET
AxoGen Releases Updated Corporate Presentation Online
Mar 05
7:32am ET
AxoGen Unveils Q4 and Full Year 2023 Financial Results
Mar 05
7:12am ET
AxoGen sees FY24 revenue $177M-$181M, consensus $178.85M
Mar 05
7:11am ET
AxoGen reports Q4 adjusted EPS (6c), consensus (10c)
No recent press releases are available for AXGN
AXGN Financials
Key terms
Ad Feedback
AXGN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
AXGN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range